Results 121 to 130 of about 209,011 (190)
Two cases of possible transmitted HIV drug resistance to all currently available integrase inhibitors, the Netherlands, 2025. [PDF]
Euro Surveillvan Kampen J +13 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
New England Journal of Medicine, 1998
Inhibitors of human immunodeficiency virus (HIV)–encoded protease, combined with nucleoside analogues with antiretroviral activity, cause profound and sustained suppression of viral replication, reduce morbidity, and prolong life in patients with HIV infection.1–3 Recent guidelines recommend that initial treatment of all HIV-infected patients include ...
Charles Flexner, Flexner Charles
exaly +7 more sources
Inhibitors of human immunodeficiency virus (HIV)–encoded protease, combined with nucleoside analogues with antiretroviral activity, cause profound and sustained suppression of viral replication, reduce morbidity, and prolong life in patients with HIV infection.1–3 Recent guidelines recommend that initial treatment of all HIV-infected patients include ...
Charles Flexner, Flexner Charles
exaly +7 more sources
Current Pharmaceutical Design, 1996
The protease encoded by the human immunodeficiency virus (HIV protease) mediates the maturation of newly formed HIV particles through proteolytic processing of the gag and gag-pol gene products. Because of its essential role in the HIV replication cycle, this enzyme represents a logical target for the treatment of HIV infection.
Dale J Kempf, Hing L Sham
exaly +8 more sources
The protease encoded by the human immunodeficiency virus (HIV protease) mediates the maturation of newly formed HIV particles through proteolytic processing of the gag and gag-pol gene products. Because of its essential role in the HIV replication cycle, this enzyme represents a logical target for the treatment of HIV infection.
Dale J Kempf, Hing L Sham
exaly +8 more sources
Enamino-oxindole HIV protease inhibitors
Bioorganic and Medicinal Chemistry Letters, 2012We have designed and synthesized a series of HIV protease inhibitors (PIs) with enamino-oxindole substituents optimized to interact with the S2' subsite of the HIV protease binding pocket. Several of these inhibitors have sub-nanomolar K(i) and antiviral IC(50) in the low nM range against WT HIV and against a panel of multi-drug resistant (MDR) strains.
Sergei Gulnik, A M Silva, Betty Yu
exaly +3 more sources
Resistance to HIV protease inhibitors
Haemophilia, 1998Summary. Resistance to the HIV‐1 protease inhibitor indinavir involves the accumulation of multiple amino acid substitutions in the viral protease. A minimum of 11 amino acid positions have been identified as potential contributors to phenotypic resistance.
C. A. Lee +5 more
openaire +2 more sources
Heterocyclic HIV-Protease Inhibitors
Current Medicinal Chemistry, 2013In the panorama of HIV protease inhibitors (HIV PIs), many efforts have been devoted to the development of new compounds with reduced peptidic nature in order to improve pharmacokinetics and pharmacodynamics features. The introduction of cyclic scaffolds in the design of new chemical entities reduces flexibility and affords more rigid inhibitors ...
CALUGI, CHIARA +2 more
openaire +3 more sources